What moved
Asia took the worst of it. The Kospi ended 4.97% lower at 6,684.37 and the Nikkei 225 finished down 2.72% at 63,492.99, with Taiwan's headline index off 2.30%. Mainland China closed weaker too, the Shanghai Composite down 1.25%, while the Hang Seng was almost unchanged at ‑0.15%.
Europe followed rather than led: the Euro Stoxx 50 closed 1.02% lower, the DAX down 0.50% and the CAC 40 down 0.76%. The FTSE 100 was the one major index to finish higher, up 0.44% at 10,697.57. In the US the selling was milder but persistent — the S&P 500 ended 0.48% lower at 7,619.98, the Nasdaq Composite down 0.56% at 26,186.41 and the Dow down 0.29%.
Why
The day's organising story was not macro but AI itself. Public comments from the heads of the largest AI labs urging a slower pace of frontier model development landed on the most crowded trade in global equities, and the damage tracked capital-expenditure exposure almost exactly: semiconductors, data-centre suppliers, optical components and the power names levered to data-centre demand were sold hardest, in Seoul and Taipei overnight, in Frankfurt and Paris through the European session, and in the US chip complex after the bell rang. That is why the drawdown was deepest where index weights are most concentrated in a handful of AI-linked manufacturers, and why the Nasdaq underperformed the Dow.
Running underneath it is the energy shock. With Saudi Arabia's East‑West pipeline — the main route that bypasses the Strait of Hormuz — shut after drone attacks, and Hormuz traffic reduced to a trickle, Brent added 1.57% to $106.25 and WTI 1.91% to $101.96, taking Brent 8.51% higher over five sessions. Diesel at a national average of $6.23 a gallon feeds through freight into almost every goods price, which is the mechanism that has turned an oil story into a rates story.
Hence Wednesday. Futures now imply roughly a 90% chance the Fed raises rates, and the equity market spent the session working out what a central bank tightening into an oil shock means for multiples. Yields themselves did not cooperate with the panic: the 10‑year brushed 5.00% intraday before ending at 4.961%, down 1.4 basis points, and the 30‑year fell 2.5 basis points to 5.329%.
Sentiment & risk appetite
Defensive, but not frightened. The VIX rose 7.95% to 17.10 — a move, yet still 51.6% below its 52‑week high — while the MOVE index of rates volatility added 2.06% to 83.90 and is up 10.19% over five sessions, which is where the real anxiety sits. Sector dispersion tells the story better than the index level: communication services gained 2.19% and health care 1.45% while technology fell 1.81%, a rotation rather than a liquidation. The safe-haven complex refused to play along — gold fell 1.57% to $4,339.70 even as the dollar index rose 0.38% to 99.50, so the haven bid went into cash, not bullion. Breadth was broadly negative outside the US: across PrimerIQ's European universe 1,846 names rose against 2,729 that fell, and in the UK 285 against 483. Oddly, crypto ran the other way, with bitcoin up 3.24% and XRP up 10.04%.
Economic calendar
Nothing of first-tier consequence printed in the US today — the domestic calendar ran to three- and six-month bill auctions, both clearing at 4.060%, which is why the tape traded on company news and crude rather than data.
The week's event is the Federal Open Market Committee, which begins its two-day meeting on Tuesday 15 September and announces on Wednesday 16 September at 2:00pm ET, followed by the chair's press conference at 2:30pm ET. Crucially this meeting carries an updated Summary of Economic Projections, so alongside the decision the market gets the committee's own revised path for rates, growth and inflation — the first formal read on how policymakers intend to treat an energy-driven inflation impulse.
Earnings
No company of consequence in our coverage was scheduled to report today, and the calendar beneath reflects that. The corporate news that actually moved prices was clinical rather than financial: GSK's weekend presentation of registrational data for its ROS1-positive lung cancer drug helped the shares close 4.74% higher at 1,854.5p and carried the FTSE 100's defensive bid. After-hours flow is thin, with S&P 500 futures trading 0.46% above their prior settlement since the bell.